Home›Stock Screener›Neuland Laboratories

Neuland Laboratories Share Price Today | Stock Price & Neuland Laboratories Share Screener

NEULANDLAB Pharmaceuticals
Live Share Price NSE
₹18935.00
▼ -40.00 (-0.21%)
2026-10-22 00:00:00
Live Share Price BSE
₹18926.95
▼ -45.40 (-0.24%)
2026-10-22 00:00:00

As of October 22, 2026, the live Neuland Laboratories share price (NSE: NEULANDLAB) is ₹18,935.00 on NSE and ₹18,926.95 on BSE, down 0.21% from the previous close, with shares trading between ₹18,530.00 and ₹19,125.00 in today's trading session, and a 52-week range of ₹11,555.00–₹23,995.00. Check NEULANDLAB 52-week high low for the annual price range and momentum. Use the Neuland Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Neuland Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹789 and net income of ₹213, with EBITDA of ₹320, an operating margin of 40.0% and a profit margin of 27.0%.

Neuland Laboratories Market Cap ₹25,242.80 Cr.
NEULANDLAB P/E Ratio (TTM) 50.78
Neuland Laboratories P/B Ratio 13.49
EPS (TTM) ₹283.71
Dividend Yield 0.17%
Debt to Equity 0.13
NEULANDLAB 52 Week High ₹23995.00
Neuland Laboratories 52 Week Low ₹11555.00
Operating Margin 40.00%
Profit Margin 27.00%
NEULANDLAB Revenue (TTM) ₹789.00
EBITDA ₹320.00
Net Income ₹213.00
Total Assets ₹2,930.00
Total Equity ₹1,875.00

Neuland Laboratories Share Price Chart

Track the current stock price of Neuland Laboratories with an interactive chart. Analyse NEULANDLAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Neuland Laboratories stock quote in one place.

The quote of ₹18,935.00 sits between the 52-week low of ₹11,555.00 and the 52-week high of ₹23,995.00, and the latest session moved -0.21% from the previous close.

Neuland Laboratories Company Profile - Fundamental Screener

Screen Neuland Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for NEULANDLAB shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE794A01010.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE794A01010

Neuland Laboratories Balance Sheet Screener

Screen NEULANDLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹2,930, up from ₹2,180 in 2025.

Latest statistics put total assets at ₹2,930 and shareholder funds at ₹1,875, with a leverage ratio of 0.13.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 2,930 2,180 1,833 1,580 1,384 1,325 1,231 1,130 1,071 886
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 1,177 955 824 758 767 716 653 542 475 466

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 346 189 122 147 180 170 163 104 146 54
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 1,875 1,525 1,283 994 841 787 710 699 558 546
Share Capital 13 13 13 13 13 13 13 13 9 9
Reserves & Surplus 1,862 1,512 1,270 981 828 774 697 686 549 537

Neuland Laboratories Income Statement Screener - Profit & Revenue Analysis

Screen Neuland Laboratories income statement and profit fundamentals. Analyze NEULANDLAB quarterly results. Neuland Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹789 and net profit was ₹213, equal to earnings per unit of ₹165.76, at an operating margin of 40%.

In that period expenses were ₹469, interest cost ₹7 and tax ₹75. The next period listed, 2026-Jun, shows revenue of ₹650 and net profit of ₹148.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar

Revenue and Expenses

Revenue 789 650 336 301 516 448 390 465 315 458 415 365 421 395 257
Expenses 469 419 277 258 359 363 278 316 249 311 287 266 280 272 217

Operating Costs and Margins

EBITDA 320 231 59 42 157 85 112 149 67 146 128 99 141 123 40
Operating Profit % 40.00% 35.00% 16.00% 12.00% 30.00% 18.00% 28.00% 28.00% 20.00% 22.00% 29.00% 27.00% 33.00% 31.00% 15.00%
Depreciation 25 27 17 20 23 24 17 16 16 16 14 14 15 15 12
Interest 7 7 2 5 5 7 4 3 1 2 4 2 4 4 3

Profit and Earnings

Profit Before Tax 288 198 39 18 129 55 92 130 49 128 110 83 122 105 24
Tax 75 50 12 4 33 14 25 32 17 26 26 21 32 23 3
Net Profit 213 148 28 14 97 41 68 98 33 102 85 62 89 81 22
EPS 165.76 115.10 21.67 10.83 75.49 31.62 52.66 76.28 25.60 79.18 65.90 48.23 69.56 63.44 16.97

Neuland Laboratories Cash Flow Screener - Liquidity Fundamentals

Screen NEULANDLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹347, and net cash flow was an outflow of ₹55.

Over the same period, investing activities used ₹423 and financing activities provided ₹21.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 347 317 261 237 60 189 57 70 11 39
Investing Activities -423 -298 -150 -61 -95 -85 -49 -77 -116 -42

Financing and Net Cash

Financing Activities 21 25 -69 -136 38 -114 -6 12 105 0
Net Cash Flow -55 44 42 40 3 -9 3 5 0 -4

Neuland Laboratories Shareholding Pattern Screener

See Neuland Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Neuland Laboratories promoter holding and ownership changes for NEULANDLAB on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 32.63%, foreign institutions 20.46%, domestic institutions 15.84% and the public 23.84%, spread across 46,304 shareholders.

The shareholder count was 46,304 in 2026-Mar, compared with 44,340 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 32.63% 32.62% 32.26% 32.68% 32.68% 32.64% 32.63% 32.74%

Institutional Investors

FII Holding 20.46% 21.08% 21.93% 22.11% 21.69% 20.60% 20.90% 24.44%
DII Holding 15.84% 16.51% 16.26% 10.97% 11.57% 13.54% 14.71% 6.54%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.40% 0.40% 0.40% 0.00% 0.40%
Public Holding 23.84% 22.88% 22.47% 25.86% 25.55% 24.72% 24.31% 27.97%
Other Holding 7.22% 6.91% 7.08% 7.99% 8.12% 8.09% 7.45% 7.91%
Shareholder Count 46,304 44,340 49,741 39,333 42,419 44,393 46,187 28,616

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Neuland Laboratories. Neuland Laboratories dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹34.00 per unit for 2026-March, a yield of 0.17%, compared with ₹12.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹34.00, ₹12.00 and ₹14.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹34.00 0.17%
2025-March ₹12.00 0.10%
2024-March ₹14.00 0.12%
2023-March ₹10.00 0.16%
2022-March ₹5.00 0.28%
2021-March ₹5.00 0.49%
2020-March ₹2.00 0.10%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Neuland Laboratories Stock Index Membership - Nifty & Sensex

See which indices include Neuland Laboratories stock. Check NEULANDLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 15 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY 500.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MULTI MFG
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMLCAP 100
NIFTY SMLCAP 250
NIFTY SMLCAP 50
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 MULTICAP
NIFTY500 SHARIAH

Neuland Laboratories Market Events Screener - Corporate Actions

Get Neuland Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Neuland Laboratories stock events that may affect NEULANDLAB share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 5, 2026, with a record date of August 5, 2026.

It is followed by Annual General Meeting dated August 4, 2026 and Dividend dated July 24, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-08-05 2026-08-05 Quarterly Result Announcement NA 4.70%
2026-08-04 2026-08-04 Annual General Meeting NA 12.11%
2026-07-24 2026-07-24 Dividend ₹ 34.00 /share 5.00%
2026-05-12 2026-05-12 Quarterly Result Announcement NA 14.69%
2026-02-09 2026-02-09 Quarterly Result Announcement NA -4.05%
2025-11-07 2025-11-07 Quarterly Result Announcement NA 8.38%
2025-07-31 2025-07-31 Quarterly Result Announcement NA 13.07%
2025-07-30 2025-07-30 Annual General Meeting NA 11.04%
2025-07-18 2025-07-18 Dividend ₹ 12.00 /share 16.23%
2025-05-15 2025-05-15 Quarterly Result Announcement NA -2.72%
2025-02-10 2025-02-10 Quarterly Result Announcement NA 2.73%
2024-11-06 2024-11-06 Quarterly Result Announcement NA -2.42%
2024-07-31 2024-07-31 Annual General Meeting NA 26.65%
2024-07-12 2024-07-13 Dividend ₹ 14.00 /share 13.26%
2023-07-11 2023-07-12 Dividend ₹ 10.00 /share 41.77%

Neuland Laboratories Competitors Screener - Peer Stocks Comparison

Screen NEULANDLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 421,995 34.85 61,674 12.69% 11,565 37.01
Divis Laboratories 242,758 83.68 11,067 13.95% 2,568 46.92
Torrent Pharmaceuticals 173,406 80.45 13,886 20.34% 2,138 32.77
Zydus Life Science 112,020 24.42 27,658 17.64% 5,026 44.73
Laurus Labs 111,310 102.03 6,868 22.01% 890 60.45
Cipla 107,049 31.90 29,045 2.24% 3,870 40.32
Dr Reddys Laboratories 102,916 32.30 35,059 3.90% 4,158 57.84
Aurobindo Pharma 95,910 25.74 34,145 5.56% 3,503 47.98
Mankind Pharma 93,988 45.45 14,636 14.85% 1,938 37.77
Lupin 89,702 16.11 29,039 26.75% 5,356 35.35

Neuland Laboratories Company Announcements - News & Reports Screener

Screen NEULANDLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 19, 2026.

The next most recent announcements are dated October 5, 2026 and September 25, 2026.

Date Update Actions
2026-10-19 Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-10-05 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-25 Closure of Trading Window -
2026-09-16 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-15 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-09-09 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-07 Disclosure Under Regulation 30 Of SEBI Listing Regulations -
2026-08-25 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-08-23 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-17 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-08-14 Intimation Regarding Completion Of US FDA Inspection -
2026-08-10 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-08-07 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-06 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-05 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-08-05 Disclosure Under Regulation 30 Of SEBI Listing Regulations -
2026-08-05 Disclosure Under Regulation 30 Of SEBI Listing Regulations -
2026-08-05 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-08-05 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-08-05 Unaudited Financial Results Of The Company For The Quarter Ended June 30 2026 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹18,935.00, within a 52-week range of ₹11,555.00 to ₹23,995.00. The P/E ratio is 50.78 and the P/B ratio is 13.49, with earnings per unit of ₹283.71. Market capitalisation stands at ₹25,242.80 Cr and the dividend yield is 0.17%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 23, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.